Bunker Hill Capital, a Boston based private equity investor in lower middle market companies, has made a growth equity investment in Courtagen Life Sciences.
Headquartered in Woburn, MA, Courtagen is a diagnostic testing services business founded in 2009 by Brian and Brendan McKernan, who currently serve as CEO and President, respectively. In 2012, they were joined by their brother, Kevin McKernan, who currently serves as Chief Scientific Officer.
“Courtagen is led by an exceptional management team that has successfully executed similar strategies and delivered superior returns to shareholders previously,” says Mark DeBlois, Managing Partner of Bunker Hill Capital. “The McKernan’s deep and technical knowledge of gene sequencing as a service and their proven ability to target and commercialise clearly defined new markets were critical factors in our decision to invest in Courtagen. In addition, the McKernans are significantly invested in the business, giving us further confidence that they are deeply committed to the long-term success of the Company.”
The current funding round will accelerate the expansion of Courtagen’s commercial operations, including expanding sales and marketing and laboratory capacity while also providing working capital to meet the growing needs of the business.
“We welcome Bunker Hill Capital to our extended team and the fresh perspective they bring,” says Brian McKernan, CEO of Courtagen. “There is an explosive growth opportunity in Next Generation Sequencing diagnostic testing, and the strong interest in Courtagen from an institutional investor like Bunker Hill Capital underscores the market’s recognition of the value and positive impact we provide to doctors, patients and their families.”
